Kairos Pharma Ltd.
KAPA | AMEX
$1.78
-$0.01 (-0.56%)
Sep 22, 2026, 10:47 AM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 40K | -120K | n/a | n/a | n/a | 40K | 40K | 40K | 40K | 40K | 40K | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | -40K | 120K | n/a | n/a | n/a | -40K | -40K | -40K | -40K | -40K | -40K | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -1.42M | -1.62M | -1.56M | -1.44M | -1.46M | -1.27M | -1.45M | -383K | -222K | -287K | -1.09M | -287K | -212K | -126K | -180K | -124K | -120K | -147K |
Interest Income | 29K | 36K | 50K | 37K | 34K | 4K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 4K | n/a | n/a | n/a |
Pretax Income | -1.39M | -1.65M | -1.37M | -1.4M | -1.42M | -1.26M | -980K | -1.05M | -253K | -323K | -1.12M | -312K | -236K | -146K | -196K | -234K | -385K | -235K |
Net Income | -1.39M | -1.65M | -1.37M | -1.4M | -1.42M | -1.26M | -980K | -1.05M | -253K | -323K | -1.12M | -312K | -236K | -146K | -196K | -234K | -385K | -235K |
Selling & General & Admin | 798K | 1.01M | 837K | 787K | 920K | 733K | 1.23M | 329K | 119K | 82K | 1.04M | 214K | 176K | 120K | 132K | 124K | 114K | 114K |
Research & Development | 619K | 684K | 538K | 608K | 496K | 493K | 172K | 14K | 63K | 165K | 7K | 33K | 36K | 6K | 48K | n/a | 6K | 33K |
Other Expenses | n/a | -113K | 308K | 40K | 40K | 40K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 1.42M | 1.58M | 1.68M | 1.44M | 1.46M | 1.27M | 1.41M | 343K | 182K | 247K | 1.05M | 247K | 212K | 126K | 180K | 124K | 120K | 147K |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | 133K | 664K | 31K | 36K | 29K | 25K | 24K | 20K | n/a | 110K | 265K | 88K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 1.42M | 1.62M | 1.56M | 1.44M | 1.46M | 1.27M | 1.45M | 383K | 222K | 287K | 1.09M | 287K | 212K | 126K | 180K | 124K | 120K | 147K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 3.06M | 3M | 2.63M | 2.89M | 2.46M | 2.27M | 1.96M | 1.56M | 1.83M | 1.51M | 1.5M | 1.6M | 1.48M | 1.48M | 1.48M | 1.46M | 1.45M | 1.45M |
Shares Outstanding (Diluted) | 3.06M | 3M | 2.63M | 2.89M | 2.46M | 2.27M | 1.96M | 1.56M | 1.83M | 1.51M | 1.5M | 1.6M | 1.48M | 1.48M | 1.48M | 1.46M | 1.45M | 1.45M |
EPS (Basic) | -0.42 | -0.55 | -0.48 | -0.49 | -0.58 | -0.56 | -0.50 | -0.67 | -0.14 | -0.21 | -0.77 | -0.19 | -0.16 | -0.10 | -0.13 | -0.16 | -0.26 | -0.16 |
EPS (Diluted) | -0.42 | -0.55 | -0.48 | -0.49 | -0.58 | -0.56 | -0.50 | -0.67 | -0.14 | -0.21 | -0.77 | -0.19 | -0.16 | -0.10 | -0.13 | -0.16 | -0.26 | -0.16 |
EBITDA | -1.37M | -1.61M | -1.33M | -1.36M | -1.38M | -1.22M | -807K | -343K | -182K | -247K | -1.05M | -247K | -172K | -86K | -156K | -84K | -80K | -107K |
EBIT | -1.39M | -1.65M | -1.37M | -1.4M | -1.42M | -1.26M | -847K | -383K | -222K | -287K | -1.09M | -287K | -212K | -126K | -196K | -124K | -120K | -147K |
Depreciation & Amortization | 22K | 40K | 40K | 40K | 40K | 40K | 40K | 40K | 40K | 40K | 40K | 40K | 40K | 40K | 40K | 40K | 40K | 40K |
Add to Watchlist
Select watchlists to add or remove KAPA